financetom
Business
financetom
/
Business
/
Northrop posts quarterly profit vs year-ago loss on surge in military equipment demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Northrop posts quarterly profit vs year-ago loss on surge in military equipment demand
Jan 30, 2025 4:11 AM

(Reuters) - U.S. defense company Northrop Grumman posted a quarterly profit on Thursday, from a year-ago loss, as headwinds from its B-21 Raider stealth bomber program eased and rising geopolitical tensions stoked demand for its military equipment.

The ongoing conflicts in the Middle East and the Russia-Ukraine war have increased demand for arms across the world and has benefited U.S. defense contractors.

However, a rise in costs owing to a slower recovery in pandemic-related supply chain snags have dented margins for companies in the sector.

Northrop expects sales in 2025 to be between $42 billion and $42.5 billion, slightly short of analysts' average estimate of $42.8 billion according to data compiled by LSEG.

It expects an adjusted per-share profit of between $27.85 and $28.25 for the year, the midpoint of which is in line with expectations.

Military equipment demand is expected to remain strong as there is likely to be increased defense spending under U.S. President Donald Trump, but investor sentiment has been clouded by potential budget cuts under the newly formed Department of Government Efficiency headed by billionaire Elon Musk.

The company, which makes the nuclear-capable B-21 Raider stealth bomber, posted fourth-quarter sales of $10.69 billion, compared with $10.64 billion a year earlier.

Northrop's adjusted per-share profit for the quarter ended Dec. 31 was $6.39. It posted a loss of $1.45 a year earlier as it booked losses related to its B21 Raider program.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cintas Lifts Annual Guidance After Posting Stronger-Than-Expected Fiscal Third-Quarter Results
Cintas Lifts Annual Guidance After Posting Stronger-Than-Expected Fiscal Third-Quarter Results
Mar 27, 2024
11:02 AM EDT, 03/27/2024 (MT Newswires) -- Shares of Cintas ( CTAS ) climbed on Wednesday after the uniform supplier reported stronger-than-expected top- and bottom-line growth for the fiscal third quarter and sweetened its full-year outlook. Revenue climbed to $2.41 billion for the three months ended Feb. 29 from $2.19 billion a year ago and surpassed the $2.39 billion average...
Verb Technology's Market.live Teams Up With TikTok; Shares Rise
Verb Technology's Market.live Teams Up With TikTok; Shares Rise
Mar 27, 2024
11:08 AM EDT, 03/27/2024 (MT Newswires) -- Verb Technology ( VERB ) said Wednesday it has entered into a partnership with TikTok Shop, making its Market.live a service provider for TikTok Shop and a designated TikTok Shop Partner. Under the partnership, TikTok Shop will direct leads to Market.live for onboarding, training, studio space rental , content creation and production services,...
Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook
Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook
Mar 27, 2024
11:01 AM EDT, 03/27/2024 (MT Newswires) -- Hamilton Thorne Ltd. ( HTLZF ) , a provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies, research, and cell biology markets, was at last look on Wednesday up 1.5% after reporting fourth-quarter earnings of $540,237, or $0.00 per diluted share, down from $980,391, or $0.00 per...
Satellos Bioscience Announces FY 2023 Results
Satellos Bioscience Announces FY 2023 Results
Mar 27, 2024
11:04 AM EDT, 03/27/2024 (MT Newswires) -- Satellos Bioscience Inc. ( MSCLF ) , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, on Wednesday reported its FY 2023 results. The company recorded a net loss of $15.9 million, compared with a net loss $11.3 million, for the year ended...
Copyright 2023-2026 - www.financetom.com All Rights Reserved